Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
NCT ID: NCT02732210
Last Updated: 2022-11-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
935 participants
OBSERVATIONAL
2011-07-06
2014-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventing Osteoporosis Using Denosumab
NCT02753283
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
NCT01668589
Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice
NCT01652690
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France
NCT02347865
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
NCT06804590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received Prolia® subcutaneously for treatment of osteoporosis consistent with local (US/Canada) product label
Exclusion Criteria
* Currently enrolled in another investigational device or drug study, or less than 6 months since ending another investigational device or drug study(s), or receiving other investigational agent(s)
* Contra-indicated for treatment with Prolia® according to the approved applicable local product label (US/Canada)
* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Chandler, Arizona, United States
Research Site
Peoria, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Hemet, California, United States
Research Site
Laguna Hills, California, United States
Research Site
Los Angeles, California, United States
Research Site
Murrieta, California, United States
Research Site
Oxnard, California, United States
Research Site
Santa Maria, California, United States
Research Site
Santa Monica, California, United States
Research Site
South Lake Tahoe, California, United States
Research Site
Victorville, California, United States
Research Site
Lakewood, Colorado, United States
Research Site
Trumbull, Connecticut, United States
Research Site
Fort Myers, Florida, United States
Research Site
Hollywood, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Kissimmee, Florida, United States
Research Site
Pembroke Pines, Florida, United States
Research Site
Sebring, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Gainesville, Georgia, United States
Research Site
Woodstock, Georgia, United States
Research Site
Alton, Illinois, United States
Research Site
Rockford, Illinois, United States
Research Site
Bettendorf, Iowa, United States
Research Site
Detroit, Michigan, United States
Research Site
East Lansing, Michigan, United States
Research Site
Lansing, Michigan, United States
Research Site
Woodbury, Minnesota, United States
Research Site
Springfield, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Butler, New Jersey, United States
Research Site
Dover, New Jersey, United States
Research Site
Albuquerque, New Mexico, United States
Research Site
Brooklyn, New York, United States
Research Site
Plainview, New York, United States
Research Site
Asheboro, North Carolina, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Tabor City, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Akron, Ohio, United States
Research Site
Centerville, Ohio, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Middletown, Ohio, United States
Research Site
Bend, Oregon, United States
Research Site
Duncansville, Pennsylvania, United States
Research Site
Lansdale, Pennsylvania, United States
Research Site
Myrtle Beach, South Carolina, United States
Research Site
Jackson, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Southlake, Texas, United States
Research Site
Chesapeake, Virginia, United States
Research Site
Midlothian, Virginia, United States
Research Site
Winchester, Virginia, United States
Research Site
Spokane, Washington, United States
Research Site
Charleston, West Virginia, United States
Research Site
Glendale, Wisconsin, United States
Research Site
Madison, Wisconsin, United States
Research Site
Calgary, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Victora, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Corunna, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Peterborough, Ontario, Canada
Research Site
Sarnia, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Woodstock, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Pointe-Claire, Quebec, Canada
Research Site
Pointe-Claire, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saint-Jean-sur-Richelieu, Quebec, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Westmount, Quebec, Canada
Research Site
Westmout, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2015 Jan;26(1):361-72. doi: 10.1007/s00198-014-2871-6. Epub 2014 Sep 19.
Silverman SL, Siris E, Belazi D, Recknor C, Papaioannou A, Brown JP, Gold DT, Lewiecki EM, Quinn G, Balasubramanian A, Yue S, Stolshek B, Kendler DL. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Arch Osteoporos. 2018 Aug 7;13(1):85. doi: 10.1007/s11657-018-0491-z.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20101218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.